Philogen
Develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
* | €62.0m | Late VC | |
| Total Funding | 000k | ||
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (62 %) | (48 %) | 850 % | (2 %) | 220 % | 498 % | (90 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (222 %) | (597 %) | 13 % | (21 %) | 58 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (278 %) | (630 %) | (23 %) | (27 %) | 61 % | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 42 % | 37 % | 5 % | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Philogen is a Swiss-Italian biotechnology company founded in 1996, specializing in the development of innovative biopharmaceuticals for treating angiogenesis-related disorders, which involve the formation of new blood vessels. The company operates in the biopharmaceutical market, focusing on the discovery, GMP production, and clinical development of targeted therapeutics, particularly antibody-based treatments. Philogen serves large pharmaceutical companies through numerous collaborative agreements and partnerships. Its business model revolves around the development and commercialization of proprietary therapeutics, generating revenue through licensing deals, milestone payments, and royalties. The company leverages its expertise in antibody engineering and targeted drug delivery to maintain a leading position in its field.
Keywords: biopharmaceuticals, angiogenesis, antibody-based therapeutics, biotechnology, clinical development, GMP production, targeted therapeutics, pharmaceutical partnerships, drug discovery, innovative treatments.